Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.54 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.53 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.53 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31256987 | 0.93 | OPRD1 (0.61) | OPRM1OPRD1OPRK1NPBWR1 | |
| SCHEMBL30527908 | 0.90 | BACE1 (0.59) | BACE1 | |
| SCHEMBL38652693 | 0.89 | BACE1 (0.59) | BACE1 | |
| SCHEMBL38652561 | 0.89 | BACE1 (0.59) | BACE1 | |
| SCHEMBL29966011 | 0.89 | BACE1 (0.59) | BACE1OPRM1OPRD1OPRK1 | |
| SCHEMBL29416071 | 0.88 | BACE1 (0.58) | BACE1 | |
| SCHEMBL31257045 | 0.88 | OPRM1 (0.56) | BACE1OPRM1OPRD1OPRK1 | |
| SCHEMBL30168332 | 0.87 | BACE1 (0.58) | BACE1OPRM1OPRD1OPRK1NPBWR1 | |
| SCHEMBL30900783 | 0.86 | TFPI (0.58) | OPRM1OPRD1OPRK1NPBWR1 | |
| SCHEMBL29494697 | 0.86 | NTSR2 (0.63) | BACE1OPRK1NTSR2NTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 844 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094973-A | T cell receptor | — | 2026-05-26 | — | — | CN | claimed |
| US-20260137817-A1 | COMBINATION CANCER IMMUNOTHERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX | GALERA LABS LLC (US) | 2026-05-21 | — | — | US | claimed |
| EP-4735471-A2 | T-CELL RECEPTORS | Ospedale San Raffaele S.r.l. (IT) | 2026-05-06 | — | — | EP | claimed |
| US-20260069697-A1 | METHOD OF TREATING CANCER | INTENSITY THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | claimed |
| CN-120082510-A | Immune cell culture medium and immune cell culture method | 广东德力泰生物医药科技有限公司 | 2025-06-03 | — | — | CN | claimed |
| WO-2025003481-A2 | T-CELL RECEPTORS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2025-01-02 | — | — | WO | claimed |
| CN-119120412-A | Vaccine based on protein CAMKII binding domain, preparation method and application | 南京邮电大学 | 2024-12-13 | — | — | CN | claimed |
| CN-118987015-A | Application of antisense oligonucleotide in preparation of medicine for treating breast cancer | 北京悦康科创医药科技股份有限公司 | 2024-11-22 | — | — | CN | claimed |
| CN-118731249-A | Simultaneous separation and determination method for terminal modified decafluorobiphenyl polypeptide drug and related substances thereof | 无锡学院 | 2024-10-01 | — | — | CN | claimed |
| US-20240299544-A1 | CANCER THERAPIES COMPRISING PEPTIDE LOADED CXCR3- AND CCR5-INDUCING DENDRITIC CELLS AND CHEMOKINE MODULATORY AGENTS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2024-09-12 | — | — | US | claimed |
| US-20240148714-A1 | Triple Negative Breast Cancer Treatment Method | EXELIXIS, INC. | 2024-05-09 | — | — | US | claimed |
| EP-4355359-A1 | CANCER THERAPIES COMPRISING PEPTIDE LOADED CXCR3- AND CCR5-INDUCING DENDRITIC CELLS AND CHEMOKINE MODULATORY AGENTS | Health Research, Inc. (US) | 2024-04-24 | — | — | EP | claimed |
| US-20230338251-A1 | METHOD OF TREATING CANCER | INTENSITY THERAPEUTICS, INC. | 2023-10-26 | — | — | US | claimed |
| US-20230190933-A1 | Immunologically Active Peptide-Biliverdin Conjugate, Preparation Method Therefor and Application Thereof | INSTITUTE OF PROCESS ENGINEERING, CHINESE ACADEMY OF SCIENCES (CN) | 2023-06-22 | — | — | US | claimed |
| US-11564987-B2 | Combination immunotherapy for treatment of triple-negative breast cancer | SLSG LIMITED LLC (US) | 2023-01-31 | — | — | US | claimed |
| WO-2022266390-A1 | CANCER THERAPIES COMPRISING PEPTIDE LOADED CXCR3- AND CCR5-INDUCING DENDRITIC CELLS AND CHEMOKINE MODULATORY AGENTS | HEALTH RESEARCH, INC. (US) | 2022-12-22 | — | — | WO | claimed |
| US-20220118119-A1 | COMBINATION CANCER IMMUNOTHERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX | BIOSSIL INC. (CA) | 2022-04-21 | — | — | US | claimed |
| US-20260146040-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | Madera Therapeutics, LLC (US) | 2026-05-28 | — | — | US | disclosed |
| WO-2022020364-A1 | PREVOTELLA HISTICOLA STRAIN C AS AN ORAL THERAPY FOR INFLAMMATORY DISEASES | EVELO BIOSCIENCES, INC. (US) | 2022-01-27 | — | — | WO | disclosed |
| US-20220025034-A1 | METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING A GM-CSF ANTAGONIST | HUMANIGEN, INC. (US) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146040-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | CTRB1, CTRB2, CPN1 | BACE1 880/4885OPRM1 1377/4885OPRD1 576/4885 |
| US-20230190933-A1 | Immunologically Active Peptide-Biliverdin Conjugate, Preparation Method Therefor and Application Thereof | VIP, CD74, WASF2 | BACE1 2003/4885OPRM1 4112/4885OPRD1 3979/4885 |
| US-20260137817-A1 | COMBINATION CANCER IMMUNOTHERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX | CD274, PDCD1, PDCD1LG2 | BACE1 3138/4885OPRM1 357/4885OPRD1 1096/4885 |
| US-20240148714-A1 | Triple Negative Breast Cancer Treatment Method | BRCA1, ABL1, STAT5B | BACE1 4511/4885OPRM1 3572/4885OPRD1 3308/4885 |
| US-20230338251-A1 | METHOD OF TREATING CANCER | PBK, GZMB, NPC1L1 | BACE1 2422/4885OPRM1 2532/4885OPRD1 3151/4885 |
| US-20220118119-A1 | COMBINATION CANCER IMMUNOTHERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX | CD274, PDCD1, PDCD1LG2 | BACE1 2880/4885OPRM1 4381/4885OPRD1 4725/4885 |
| US-20260069697-A1 | METHOD OF TREATING CANCER | PBK, GZMB, KLRK1 | BACE1 1688/4885OPRM1 2071/4885OPRD1 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.